Polynoma is an immuno-oncology company developing seviprotimut-L, a novel polyvalent shed antigens vaccine for the adjuvant treatment of melanoma.
Chief Operating OfficerPatrick Mallon is Chief Operating Officer of Polynoma LLC (“Polynoma”) and is responsible for the management of preclinical, clinical development and operations, regulatory affairs, CMC/manufacturing, commercial development and quality functions of the Company. Mr. Mallon joined Polynoma in 2012. He holds a Bachelor’s degree in Medical Technology, and has extensive senior and C-level executive experience… Read More
Chief Financial OfficerAndrew Buckland is Polynoma’s Chief Financial Officer and is responsible for financial operations. Mr. Buckland joined Polynoma in 2012. He earned an MBA from the University of California, Irvine and holds a BA (with Honors) from the University of the West of England. Mr. Buckland has extensive experience in the development of financial operations within both large multinational… Read More
Chief Technology OfficerMelvin Toh is Chief Technology Officer responsible for technology and clinical research and development activities of Polynoma. He is also the Vice President and Chief Scientific Officer of CK Life Sciences Int’l., (Holdings) Inc., Polynoma’s parent company. He holds Bachelor of Medicine and Bachelor of Surgery degrees from the National University of Singapore and a Master of Science degree in Epidemiology… Read More
Alan Yu is Polynoma’s Chairman and is the Vice President and Chief Operating Officer of CK Life Sciences (“CKLS”) where he is responsible for the commercial activities, including manufacturing and marketing of all product applications. He has been a member of CKLS Nomination Committee since January 2019. He holds a Bachelor of Arts degree and a Master’s degree in Business Administration. Read More